RESEARCH TRIANGLE PARK, N.C., September 27, 2016 /PRNewswire/ — Envisia Therapeutics, a medical-phase biotechnology organization centered on the improvement of book expanded-launch treatments in ophthalmology, introduced today that it’ll provide in the Ophthalmic Drug Development Summit happening September 26 – 28, 2016 in California, DC.
Dr. Tomas Navratil, Senior Vice President, Improvement at Envisia will show Targeting Top Reasons For Blindness with Nano and Micro-Technology-Centered Continual Drug-Delivery from 1:thirty – 2:00pm Eastern Time on Friday, July 28, 2016.
Envisia is using the Business’s distinctive PRINTING® system engineering to build up items for that three top reasons for vision damage and blindness – glaucoma, era-related macular degeneration (AMD), and diabetic macular edema (DME).
ABOUT ENVISIA THERAPEUTICS&industry;
Envisia Therapeutics is just a privately-held biotechnology organization centered on the improvement of book ocular treatments. Envisia is using the initial and effective qualities of the PRINTING® engineering system to build up treatments to get a number of ocular problems, you start with ENV515 for glaucoma. ENV515 is just a book, prolonged-release formula of the promoted prostaglandin analogue using the potential to somewhat control vision damage and disease development through enhanced merchandise efficiency and individual compliance. Envisia is definitely researching the usage of the Business’s special engineering to build up items for additional essential ocular ailments including age-related macular degeneration (AMD) and diabetic macular edema (DME). Envisia is found in Research Triangle Park, New York. To find out more, please visit www.envisiatherapeutics.com.
SUPPLY Envisia Therapeutics